In 1975, the National Institute on Aging was created, and within a year, Alzheimer\'s disease (AD) was declared the fourth leading cause of death and the most prevalent dementia disorder. However, as a new post doc in 1980, I soon discovered the research value of imaging in AD, then largely limited to structural CT and 133 Xe flow studies, was marked by doubts of utility (limited to recognizing clinically silent focal brain lesions), little public awareness (dementia vs old timers disease-really!), and limited funding (see [Fig. 1](#fig1){ref-type="fig"} which begins in 1985 as older funding records are not available). The past 30 years show that the NIH consistently funded imaging research at well under 1% of the cost of Medicare and Medicaid spending on AD.

By 1996, just 20 years later, the science of imaging the dementias experienced global recognition in large measure benefitting from technological advances. Zaven Khachaturian\'s AD centers were highly successful incubators of imaging projects, the structural imaging prediction of future AD from the MCI stage was replicated, longitudinal MRI and FDG-PET studies were de rigueur, a preclinical diagnosis was in sight, imaging and neuropathology were irrevocably linked, and combined imaging and CSF studies added needed pathologic specificity to diagnosis. The future optimistically hinted of contributions of PET-based molecular diagnosis, the NIH-NIA dream leadership team of Richard Hodes, Neil Buckholtz, Marcelle Morrison-Bogorad, and Tony Phelps were conjuring up more big science, and imaging outcomes entered clinical trials. The world had now come to fear the coming AD epidemic and a rising tide of financial opportunity lifted all boats.

In 1996 at the Fifth International Conference on Alzheimer\'s Disease and Related Disorders in Osaka, Japan, Philip Scheltens and I accepted the invitation of the Alzheimer\'s Association\'s conference program directors to co-chair an imaging focused satellite interest group (later to be called the Alzheimer\'s Imaging Consortium or AIC). The inaugural AIC was planned for the 1998 International Conference on Alzheimer\'s Disease and Related Disorders in Amsterdam. Philip and I worked with the association to assemble a representative and interactive program, and I was given the honor to deliver the first imaging plenary the day before at the "big" meeting, but all did not go entirely as planned. The first AIC symposium overflowed with participants in a too small and poorly air conditioned conference room. Still, AIC \#1 was a scientific and social success. However, my 30-minute talk was cut 6 minutes, short by a chair whose timing erred. As a result, I omitted the more challenging part of my presentation, an example of how imaging could go beyond description and prediction to mechanism identification. Well, in retrospect, it probably was for the best that I did not deliver my example. Evidence supporting AD as an energy deficient disorder did not fare well over the years. But, the need to reveal mechanisms of neurodegenerative disease, in humans during life, has endured and is today more needed than ever. Such was the vision Philip and I intended to promote with the AIC. Philip Scheltens gave the next imaging plenary 2 years later.

I think a vital part of our responsibility as scientists is to review, comment, and celebrate the progress and accomplishments of our peers. In 1999, my colleagues, Heiko Braak, Khalid Iqbal, Bill Jagust, Judes Poirier, Barry Reisberg, Jerzy Wegiel, and Thomas Wisniewski, and I elected to donate 100% of the proceeds from our 1999 textbook, "An Atlas of Alzheimer\'s Disease" with Parthenon Publishing to create two "neuroimaging prizes". With the guidance of Zaven Kachaturian, Richard Frank, and Peter Snyder, we convinced the association to accept our donation and deliver the first awards in 2006. Today these awards, renamed the "de Leon Prize in Neuroimaging," are managed and funded by the Alzheimer\'s Association and are awarded at the annual AIC meeting that accompanies the Alzheimer\'s Association International Conference (AAIC). I am confident we are doing the right thing, having honored as of 2016, 22 of our most talented colleagues. I only wish there were more resources.

Now just weeks after the 2016 Toronto AAIC meeting which marked the 20th anniversary of the founding of AIC, my AIC colleagues and I continue to salute those who dare to think creatively, break barriers and take us all to a new level of understanding of Alzheimer\'s disease through brain imaging.

My thanks and appreciation go to Dr. Peter Snyder, Editor-in-Chief of "*Alzheimer\'s & Dementia: Diagnosis, Assessment & Disease Monitoring*" and Dr. Liana Apostolova, guest editor for this special volume on neuroimaging advances, for their excellent scientific contributions, our friendship, and for offering me the chance to express my appreciation. The next 20 years should be pretty interesting.
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